Stocks Health care TIL
NASDAQ · Health careInstil Bio, Inc. (TIL)
It posted a net loss of $30.3M. At June 30, 2026 it held $5.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Instil Bio, Inc. does
Instil Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TIL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$71.4M | -$10.70 | n/a |
| 2024 | n/a | -$74.1M | -$11.39 | -$55.7M |
| 2023 | n/a | -$156.1M | -$24.00 | -$102.7M |
| 2022 | n/a | -$223.2M | -$34.46 | -$264.8M |
| 2021 | $0 | -$156.8M | -$29.65 | -$180M |
| 2021 | $138K | -$37.7M | -$47.28 | -$80.4M |
Latest SEC filings
What Instil Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- June 11, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026
- May 15, 2026
- April 24, 2026
- April 24, 2026Additional proxy material DEFA14A
- April 24, 2026Proxy statement DEF 14A
- April 3, 2026Auditor change 8-K
- March 27, 2026
Questions about TIL
What does Instil Bio, Inc. do?
Instil Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TIL.
Is Instil Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $30.3M.
When did Instil Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.
Similar companies
Follow TIL
Get an email when Instil Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TIL: get an email when it filesWhere the numbers come from
Financial figures are the values Instil Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.